Harley Anderson Haynes, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Telangiectasis | 1 | 2009 | 76 | 0.330 |
Why?
|
| Ergotamines | 1 | 2004 | 4 | 0.250 |
Why?
|
| Belladonna Alkaloids | 1 | 2004 | 4 | 0.250 |
Why?
|
| Phenobarbital | 1 | 2004 | 192 | 0.230 |
Why?
|
| Skin Diseases | 5 | 2013 | 1065 | 0.230 |
Why?
|
| Cicatrix | 1 | 2009 | 764 | 0.220 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2003 | 124 | 0.210 |
Why?
|
| Lymphatic Diseases | 1 | 2003 | 324 | 0.200 |
Why?
|
| Hot Flashes | 1 | 2004 | 317 | 0.200 |
Why?
|
| Dermatitis | 1 | 2003 | 197 | 0.200 |
Why?
|
| Keratosis, Seborrheic | 2 | 2012 | 27 | 0.190 |
Why?
|
| Paraneoplastic Syndromes | 2 | 2012 | 150 | 0.170 |
Why?
|
| Exanthema | 1 | 2003 | 501 | 0.160 |
Why?
|
| Photosensitivity Disorders | 2 | 1990 | 78 | 0.150 |
Why?
|
| Drug Hypersensitivity | 4 | 2004 | 883 | 0.140 |
Why?
|
| Drug Labeling | 1 | 1998 | 232 | 0.140 |
Why?
|
| Leukemia | 1 | 2003 | 1508 | 0.130 |
Why?
|
| Dermatologic Agents | 1 | 1998 | 278 | 0.130 |
Why?
|
| Mycosis Fungoides | 5 | 1983 | 163 | 0.120 |
Why?
|
| Dermatomyositis | 1 | 1997 | 224 | 0.120 |
Why?
|
| Anticonvulsants | 1 | 2004 | 1917 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2012 | 3523 | 0.120 |
Why?
|
| Vasculitis | 2 | 2009 | 521 | 0.110 |
Why?
|
| Drug Approval | 1 | 1998 | 741 | 0.100 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 455 | 0.100 |
Why?
|
| Skin Neoplasms | 11 | 2005 | 5670 | 0.100 |
Why?
|
| Teaching | 1 | 1998 | 1174 | 0.090 |
Why?
|
| Dermatology | 4 | 2014 | 872 | 0.090 |
Why?
|
| Nose Diseases | 1 | 2010 | 79 | 0.090 |
Why?
|
| Cutis Laxa | 1 | 2009 | 29 | 0.090 |
Why?
|
| Measles | 1 | 1990 | 168 | 0.080 |
Why?
|
| Specialization | 1 | 2013 | 777 | 0.080 |
Why?
|
| Clinical Clerkship | 1 | 2014 | 532 | 0.080 |
Why?
|
| Angiomatosis | 1 | 1986 | 49 | 0.070 |
Why?
|
| Herpes Simplex | 1 | 2010 | 470 | 0.070 |
Why?
|
| Nose | 1 | 2010 | 509 | 0.070 |
Why?
|
| Polyarteritis Nodosa | 1 | 1986 | 66 | 0.070 |
Why?
|
| Gingivitis | 1 | 1986 | 124 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 1998 | 2291 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 992 | 0.070 |
Why?
|
| Patient Admission | 1 | 2013 | 1380 | 0.070 |
Why?
|
| Students, Medical | 1 | 1998 | 1862 | 0.060 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2014 | 1007 | 0.060 |
Why?
|
| Pyoderma | 1 | 1983 | 8 | 0.060 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1984 | 41 | 0.060 |
Why?
|
| Prednisone | 2 | 1984 | 1575 | 0.060 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1983 | 85 | 0.050 |
Why?
|
| Nephritis | 1 | 1984 | 158 | 0.050 |
Why?
|
| Azathioprine | 1 | 1984 | 355 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2009 | 931 | 0.050 |
Why?
|
| Ampicillin | 1 | 1982 | 138 | 0.050 |
Why?
|
| Candidiasis, Cutaneous | 1 | 1981 | 5 | 0.050 |
Why?
|
| Ecthyma | 1 | 1981 | 7 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 2103 | 0.050 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2005 | 545 | 0.050 |
Why?
|
| Primary Myelofibrosis | 1 | 1983 | 215 | 0.050 |
Why?
|
| Injections, Intravenous | 4 | 1997 | 1420 | 0.050 |
Why?
|
| Curriculum | 1 | 2014 | 3604 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 1984 | 412 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2013 | 3528 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 1364 | 0.040 |
Why?
|
| Interferon-alpha | 2 | 2000 | 895 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2004 | 1962 | 0.040 |
Why?
|
| Pruritus | 1 | 1982 | 361 | 0.040 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2002 | 300 | 0.040 |
Why?
|
| Pigmentation Disorders | 1 | 1978 | 101 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 11493 | 0.040 |
Why?
|
| Humans | 40 | 2014 | 744220 | 0.030 |
Why?
|
| Menopause | 1 | 2004 | 1626 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1997 | 388 | 0.030 |
Why?
|
| Diagnosis, Differential | 6 | 2005 | 12961 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2005 | 2924 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 2942 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 5 | 1972 | 485 | 0.030 |
Why?
|
| Uveitis | 1 | 1978 | 375 | 0.030 |
Why?
|
| Alopecia | 1 | 1978 | 381 | 0.030 |
Why?
|
| Adult | 18 | 2013 | 214035 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2003 | 1352 | 0.030 |
Why?
|
| Allergy and Immunology | 1 | 2014 | 169 | 0.030 |
Why?
|
| Female | 18 | 2013 | 380197 | 0.030 |
Why?
|
| Middle Aged | 17 | 2013 | 213367 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2000 | 3474 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2009 | 5180 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 1998 | 1583 | 0.020 |
Why?
|
| Melanoma | 2 | 2000 | 5475 | 0.020 |
Why?
|
| Contrast Media | 1 | 1984 | 5300 | 0.020 |
Why?
|
| Measles virus | 1 | 1990 | 68 | 0.020 |
Why?
|
| Methotrexate | 1 | 1997 | 1720 | 0.020 |
Why?
|
| Nephrology | 1 | 2014 | 263 | 0.020 |
Why?
|
| Mupirocin | 1 | 2010 | 56 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1999 | 1333 | 0.020 |
Why?
|
| Acyclovir | 1 | 2010 | 272 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 2009 | 65 | 0.020 |
Why?
|
| Male | 21 | 2013 | 350027 | 0.020 |
Why?
|
| Nitrogen Mustard Compounds | 2 | 1967 | 45 | 0.020 |
Why?
|
| Skin | 4 | 1984 | 4363 | 0.020 |
Why?
|
| Rheumatology | 1 | 2014 | 576 | 0.020 |
Why?
|
| Chlorambucil | 1 | 1967 | 43 | 0.020 |
Why?
|
| Nasopharynx | 1 | 1990 | 379 | 0.020 |
Why?
|
| Carcinoma | 1 | 1999 | 2375 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 2009 | 372 | 0.020 |
Why?
|
| Hodgkin Disease | 4 | 1972 | 1415 | 0.020 |
Why?
|
| Disease Progression | 1 | 2003 | 13280 | 0.020 |
Why?
|
| Simplexvirus | 1 | 2010 | 802 | 0.020 |
Why?
|
| Aged | 9 | 2013 | 163253 | 0.020 |
Why?
|
| Vinblastine | 1 | 1967 | 490 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1990 | 2505 | 0.020 |
Why?
|
| Odontogenic Tumors | 1 | 1966 | 45 | 0.020 |
Why?
|
| Genetics | 1 | 1966 | 112 | 0.020 |
Why?
|
| Pilomatrixoma | 1 | 2005 | 23 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1990 | 1538 | 0.020 |
Why?
|
| Syndrome | 2 | 1983 | 3250 | 0.020 |
Why?
|
| Hair Diseases | 1 | 2005 | 74 | 0.020 |
Why?
|
| Hemangiosarcoma | 1 | 1986 | 239 | 0.010 |
Why?
|
| Nevus | 1 | 1966 | 204 | 0.010 |
Why?
|
| Protective Devices | 1 | 1984 | 71 | 0.010 |
Why?
|
| Gangrene | 1 | 1983 | 82 | 0.010 |
Why?
|
| Plastics | 1 | 1984 | 123 | 0.010 |
Why?
|
| Endocrine System Diseases | 1 | 1966 | 248 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1967 | 1791 | 0.010 |
Why?
|
| Basal Ganglia | 1 | 1966 | 545 | 0.010 |
Why?
|
| Mohs Surgery | 1 | 2005 | 197 | 0.010 |
Why?
|
| Cardiology | 1 | 2014 | 1668 | 0.010 |
Why?
|
| Cyclophosphamide | 2 | 1967 | 2236 | 0.010 |
Why?
|
| Radiodermatitis | 1 | 1982 | 60 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1966 | 601 | 0.010 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 1966 | 484 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1999 | 5257 | 0.010 |
Why?
|
| Candidiasis | 1 | 1983 | 366 | 0.010 |
Why?
|
| Cysts | 1 | 1966 | 679 | 0.010 |
Why?
|
| Biopsy | 2 | 1984 | 6757 | 0.010 |
Why?
|
| Deoxyuracil Nucleotides | 1 | 1999 | 13 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 6612 | 0.010 |
Why?
|
| beta Catenin | 1 | 2005 | 1059 | 0.010 |
Why?
|
| Thymine Nucleotides | 1 | 1999 | 63 | 0.010 |
Why?
|
| Lymphocytes | 4 | 1984 | 2617 | 0.010 |
Why?
|
| Necrosis | 1 | 1983 | 1643 | 0.010 |
Why?
|
| Veins | 1 | 1983 | 769 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 1982 | 297 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2014 | 4687 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1990 | 4559 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 1999 | 290 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 10949 | 0.010 |
Why?
|
| Methoxsalen | 1 | 1976 | 21 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2000 | 13668 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2002 | 1770 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 1256 | 0.010 |
Why?
|
| Erythema | 1 | 1976 | 257 | 0.010 |
Why?
|
| Skin Tests | 4 | 1972 | 612 | 0.010 |
Why?
|
| Risk Factors | 2 | 2000 | 72280 | 0.010 |
Why?
|
| Melanocytes | 1 | 1978 | 515 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1999 | 1616 | 0.010 |
Why?
|
| Prognosis | 3 | 1979 | 29050 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1984 | 6485 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1966 | 2525 | 0.010 |
Why?
|
| Mechlorethamine | 2 | 1976 | 136 | 0.010 |
Why?
|
| Cryosurgery | 1 | 1978 | 452 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2000 | 2914 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1999 | 1836 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1976 | 1060 | 0.010 |
Why?
|
| Time Factors | 3 | 2000 | 40063 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 11368 | 0.010 |
Why?
|
| Neutrophils | 1 | 1983 | 3717 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 4929 | 0.010 |
Why?
|
| United States | 1 | 1998 | 69867 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 8628 | 0.010 |
Why?
|
| Nitrobenzenes | 4 | 1972 | 65 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2000 | 6893 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 77426 | 0.010 |
Why?
|
| Television | 1 | 1972 | 409 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 1969 | 313 | 0.010 |
Why?
|
| Skin Manifestations | 1 | 1967 | 17 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1978 | 4841 | 0.000 |
Why?
|
| Young Adult | 1 | 2013 | 56436 | 0.000 |
Why?
|
| Adolescent | 3 | 2013 | 85759 | 0.000 |
Why?
|
| Glycols | 1 | 1965 | 59 | 0.000 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 2732 | 0.000 |
Why?
|
| Remission, Spontaneous | 2 | 1978 | 380 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 7908 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1982 | 6352 | 0.000 |
Why?
|
| Desensitization, Immunologic | 1 | 1967 | 483 | 0.000 |
Why?
|
| Ethanol | 1 | 1965 | 1342 | 0.000 |
Why?
|
| Photochemistry | 1 | 1976 | 238 | 0.000 |
Why?
|
| Ultraviolet Therapy | 1 | 1976 | 81 | 0.000 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1976 | 228 | 0.000 |
Why?
|
| Lectins | 2 | 1969 | 513 | 0.000 |
Why?
|
| Antigens | 2 | 1972 | 1466 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1999 | 53280 | 0.000 |
Why?
|
| Skin Pigmentation | 1 | 1976 | 282 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1999 | 57768 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 1999 | 63119 | 0.000 |
Why?
|
| Leukopenia | 1 | 1972 | 208 | 0.000 |
Why?
|
| Mumps | 1 | 1972 | 64 | 0.000 |
Why?
|
| Color | 1 | 1972 | 307 | 0.000 |
Why?
|
| Mumps virus | 1 | 1969 | 24 | 0.000 |
Why?
|
| Histoplasma | 1 | 1969 | 41 | 0.000 |
Why?
|
| Streptolysins | 1 | 1969 | 55 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1976 | 3913 | 0.000 |
Why?
|
| Candida | 1 | 1969 | 172 | 0.000 |
Why?
|
| Hemagglutination Tests | 1 | 1967 | 75 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1972 | 1584 | 0.000 |
Why?
|
| Dosage Forms | 1 | 1967 | 56 | 0.000 |
Why?
|
| Injections, Intradermal | 1 | 1967 | 117 | 0.000 |
Why?
|
| Dermatitis, Contact | 1 | 1967 | 129 | 0.000 |
Why?
|
| Recurrence | 1 | 1978 | 8343 | 0.000 |
Why?
|
| Indians, North American | 1 | 1969 | 353 | 0.000 |
Why?
|
| Alcohol Oxidoreductases | 1 | 1965 | 170 | 0.000 |
Why?
|
| Risk | 1 | 1976 | 9685 | 0.000 |
Why?
|
| Immunization | 1 | 1967 | 1256 | 0.000 |
Why?
|
| DNA | 1 | 1976 | 7303 | 0.000 |
Why?
|
| Antibodies | 1 | 1967 | 2461 | 0.000 |
Why?
|
| Phenotype | 1 | 1976 | 16365 | 0.000 |
Why?
|
| Lymphoma | 1 | 1967 | 1873 | 0.000 |
Why?
|
| Child | 2 | 1972 | 77679 | 0.000 |
Why?
|